MDM2--master regulator of the p53 tumor suppressor protein.

By J. Momand, Hsiao-Huei Wu, G. Dasgupta. Gene, 2000

668 citations recorded by the source corpus.

Subfields: Biotechnology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/b4017ebf3b6316ef688225f6adefc0af3165c4da

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biotechnology

1. Carol Prives
2. Moshe Oren

In Molecular Biology

1. Yosef Shiloh
2. D. Reinberg
3. M. Kastan
4. Paul Tempst
5. Carol Prives
6. S. Chuikov
7. Moshe Oren
8. K. Strebhardt

In Oncology

1. Yosef Shiloh
2. M. Kastan
3. Carol Prives
4. Moshe Oren
5. K. Strebhardt
6. Stephen W. Fesik
7. J. Bartek
8. J. Lukas

Citations in the corpus

• Promoting apoptosis as a strategy for cancer drug discovery (2005, background): “MDM2 antagonists MDM2 is a protein that binds to the tumour suppressor p53 and negatively regulates its activity and stabilit”
• ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. (2001, background): “The positions of the main identified structural domains of the protein ( Momand et al. 2000 ) are also indicated.”
• High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. (2015, neutral): “The canonical p53 protein degradation pathway involves ubiquitination by the E3 protein-ubiquitin ligase MDM2 (Figure 4C) (Momand et al., 2000).”
• Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53 (2004, background): “The ability of Mdm2 to degrade p53 requires shuttling between the nucleus and the cytoplas”
• Regulation of p53 activity through lysine methylation (2004, background): “Phosphorylation of several residues at the amino terminus of p53 has been shown to affect its interaction with MDM2, which targets p53 for ubiquitin-mediated degradatio”
• Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy (2010, background): “Additional experiments showed that the long-term downregulation of PLK1 correlates with reduced levels of MDM2, a p53-specific E3 ubiquitin ligase that acts as a p53 antagonis”
• Decision making by p53: life, death and cancer (2003, background): “,(12) Deb(13) and Momand et al.(14)) Mdm2 is a product of a proto-oncogene, amplified or otherwise overexpressed in”
• The proteasome: a suitable antineoplastic target (2004, neutral): “An estimated 50% of human tumours have mutations in p53, and many other tumours are associated with alterations in the positive (ARF) or negative ( MDM2 ) regulators of p53 (Ref”
• Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies (2016, background): “The p53 oncosuppressor protein is normally kept at low level because subject to negative regulation by MDM2dependent proteasome degradation [132]; in response to genotoxic stress, however, p53 undergoes posttranslational modifications that allow the protein to escape MDM2 control, accumulate, and be”